当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Estimating the effect of measles vaccination on child growth using 191 DHS from 65 low- and middle-income countries.

Estimating the effect of measles vaccination on child growth using 191 DHS from 65 low- and middle-income countries.

Abstract：

BACKGROUND:Childhood vaccinations reduce morbidity and mortality and are highly cost-effective. They may also protect children from malnutrition and lead to improved child growth. Stunting, wasting and underweight are targets used to monitor progress towards the achievement of the sustainable development goals (SDGs). METHODS:We use data from Demographic and Health Surveys (DHS) covering the period from 1990 to 2017 to estimate the effect of measles vaccination at 12 months of age on stunting, wasting, and underweight. For causal estimation, we use household- and mother-fixed effects, which allows us to compare outcomes across siblings while controlling for all observed and unobserved confounders that are shared by the siblings, such as household social characteristics and home location. In addition, we control for a wide range of sibling-varying confounders, including sex, age, birth order and mother's age at birth, as well as vaccination with diphtheria-tetanus-polio (DPT), as a broad indicator of general likelihood to receive vaccinations. RESULTS:Our samples include 347,808 individuals in 132 surveys from 59 countries (for stunting), 430,963 individuals in 190 surveys from 65 countries (for wasting), and 353,520 individuals in 130 surveys from 59 countries (for underweight). Measles vaccination is associated with significantly reduced odds of stunting (odds ratio 0.90 [95% CI 0.86-0.94], p < 0.001) and underweight (odds ratio 0.90 [95% CI 0.86-0.95], p < 0.001). The association with wasting is weaker and not statistically significant (odds ratio 0.95 [95% CI 0.89-1.02], p = 0.143). Our results remain robust across several alternative specifications of our regression models. CONCLUSIONS:Measles vaccination substantially reduces stunting and underweight among children in low- and middle-income countries. Increasing measles coverage from the current low to near-universal levels would provide a large boost to child growth and the attainment of the SDGs.

journal_name

Vaccine

journal_title

Vaccine

authors

Bogler L,Jantos N,Bärnighausen T,Vollmer S

doi

10.1016/j.vaccine.2019.06.054

subject

Has Abstract

pub_date

2019-08-14 00:00:00

pages

5073-5088

issue

35

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(19)30816-3

journal_volume

37

pub_type

杂志文章

相关文献

VACCINE文献大全
  • A comparison of different vaccination schemes used in sheep combining inactivated bluetongue vaccines against serotypes 4 and 8.

    abstract：:Eight different vaccination schemes using four commercially available inactivated Bluetongue vaccines against serotypes 4 and 8 in three different combinations (setting 1-3) were tested under field conditions for their ability to generate a measurable immune response in sheep. Animals of setting 1 (groups A-D) were si...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.08.011

    authors： Hilke J,Strobel H,Woelke S,Stoeter M,Voigt K,Grimm L,Meilwes J,Punsmann T,Blaha I,Salditt A,Rohn K,Bastian M,Ganter M

    更新日期：2019-09-16 00:00:00

  • Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives.

    abstract：INTRODUCTION:The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At the end of the decade, significant progress has been made but four of the five GVAP goals are likely to be missed. This report describes a set of surve...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.05.048

    authors： Hwang A,Veira C,Malvolti S,Cherian T,MacDonald N,Steffen C,Jones I,Hinman A,Mantel C

    更新日期：2020-07-14 00:00:00

  • Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.

    abstract：BACKGROUND:Human papillomavirus (HPV) vaccination offers potential for primary prevention of HPV-related pre-cancers and cancers as demonstrated in clinical trials. Mathematical models have estimated the potential real-life impact of vaccination on the burden of cervical cancer (CC). However, these are restricted to ev...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.11.049

    authors： Van Kriekinge G,Castellsagué X,Cibula D,Demarteau N

    更新日期：2014-02-03 00:00:00

  • Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults.

    abstract：:T-lymphocyte responses to influenza vaccination were measured in healthy young and older adult volunteers. All participants were vaccinated with the 1995-96 trivalent influenza vaccine. Cytokine and granzyme B levels were measured in peripheral blood mononuclear cells (PBMC) cultures after virus stimulation, prior to ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00133-9

    authors： McElhaney JE,Upshaw CM,Hooton JW,Lechelt KE,Meneilly GS

    更新日期：1998-11-01 00:00:00

  • Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile.

    abstract：:A placebo-controlled, double-blind study on the efficacy of a hepatitis A vaccine (SmithKline Beecham Biologicals) was started in a region of Chile in September 1990, using hepatitis B vaccine as control. A total of 260 healthy children, 6-15 years of age, negative for antibody to hepatitis A virus (anti-HAV), antibod...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0264-410x(92)90573-3

    authors： Riedemann S,Reinhardt G,Frösner GG,Ibarra H,Moraleda L,Hering V,Siegel F,Toledo C,Leon J,Gonzalez JL

    更新日期：1992-01-01 00:00:00

  • Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies.

    abstract：:This study evaluated the seroprevalence of poliovirus types 1, 2 and 3 antibodies and vaccination coverage in 780 subjects aged between 7 months and 39 years in Montevideo, Uruguay, where oral polio vaccine (OPV) is used. Antibody titers were measured and seroprotection rates and geometric mean titers (GMTs) were comp...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.02.042

    authors： Pírez MC,Olivera I,Diabarboure H,Montano A,Barañano R,Badía F,Bonnet MC

    更新日期：2009-05-05 00:00:00

  • Fusion of antigen to Fas-ligand in a DNA vaccine enhances immunogenicity.

    abstract：:DNA vaccines have considerable potential for the prophylaxis and therapy of a range of diseases, but their potential has not been realised largely due to poor immunogenicity. Fas ligand is a pro-apoptotic molecule, able to induce death of Fas expressing cells. We describe the construction of a DNA vaccine encoding a c...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2006.11.059

    authors： Nimal S,Thomas MS,Heath AW

    更新日期：2007-03-08 00:00:00

  • Status of vaccine research and development for norovirus.

    abstract：:The global health community is beginning to gain an understanding of the global burden of norovirus-associated disease, which appears to have significant burden in both developed- and developing-country populations. Of particular importance is the growing recognition of norovirus as a leading cause of gastroenteritis ...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2016.03.077

    authors： Riddle MS,Walker RI

    更新日期：2016-06-03 00:00:00

  • The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations.

    abstract：:Real, perceived and unknown adverse events secondary to vaccinations are a source of concern for care providers of children. In the USA large linked databases have provided helpful information regarding the safety of vaccines. Very little prospectively collected data on vaccine safety is available from resource poor c...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00633-3

    authors： Ali M,Canh DG,Clemens JD,Park JK,von Seidlein L,Thiem VD,Tho le H,Trach DD

    更新日期：2003-04-02 00:00:00

  • Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus.

    abstract：:The highly pathogenic avian influenza (HPAI) H5N1 viruses and their spillover into the human population pose substantial economic and public health threats. Although antiviral drugs have some effect in treating influenza infection, vaccination is still the most effective intervention to prevent possible pandemic outbr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.01.051

    authors： Lu Y,Landreth S,Liu G,Brownlie R,Gaba A,Littel-van den Hurk SVD,Gerdts V,Zhou Y

    更新日期：2020-02-28 00:00:00

  • Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

    abstract：:Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.01.089

    authors： Khromava AY,Eidex RB,Weld LH,Kohl KS,Bradshaw RD,Chen RT,Cetron MS,Yellow Fever Vaccine Safety Working Group.

    更新日期：2005-05-09 00:00:00

  • Expression of HIV-1 envelope gene by recombinant avipox viruses.

    abstract：:Recombinant canarypox (CP) and fowlpox (FP) viruses that contained two forms of the HIV-1 (SF2 strain) env gene were engineered and their expression analysed in chick, simian and human cells. These vectors can efficiently replicate in avian but not in mammalian cells, in which infection is abortive. The two forms, con...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(94)90180-5

    authors： Radaelli A,De Giuli Morghen C

    更新日期：1994-09-01 00:00:00

  • Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.

    abstract：:Therapeutic immunization of HIV-1-infected individuals with or without anti-retroviral therapy is a new promising disease prevention. To induce a new cytotoxic T(CD8) lymphocyte (CTL) immunity during chronic HIV-1 infection 15 infrequently targeted but conserved HLA-supertype binding CTL epitopes from Gag, Pol, Nef, E...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.07.025

    authors： Fomsgaard A,Karlsson I,Gram G,Schou C,Tang S,Bang P,Kromann I,Andersen P,Andreasen LV

    更新日期：2011-09-16 00:00:00

  • Antibiotic resistance in Vibrio cholerae: Understanding the ecology of resistance genes and mechanisms.

    abstract：:The unique genetic makeup and remarkable competency of Vibrio cholerae are the key factors that help the cholera pathogen adapt rapidly to adverse environmental conditions and resist the detrimental effect of antimicrobial agents. In the last few decades, V. cholerae that causes acute watery diarrhoeal disease cholera...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2019.06.031

    authors： Das B,Verma J,Kumar P,Ghosh A,Ramamurthy T

    更新日期：2020-02-29 00:00:00

  • Modelling the epidemiological impact of rotavirus vaccination in Germany--a Bayesian approach.

    abstract：BACKGROUND:Rotavirus (RV) infection is the primary cause of severe gastroenteritis in children aged <5 years in Germany and worldwide. In 2013 the German Standing Committee on Vaccination (STIKO) developed a national recommendation for routine RV-immunization of infants. To support informed decision-making we predicted...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.06.090

    authors： Weidemann F,Dehnert M,Koch J,Wichmann O,Höhle M

    更新日期：2014-09-08 00:00:00

  • Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach.

    abstract：:Currently, infections of hand, foot and mouth disease (HFMD) due to Human Enterovirus 71 (EV71) cannot be prevented or treated, as there are no suitable vaccines or antiviral drugs. This study aimed to identify potential vaccine candidates for EV71 using in silico analysis of its viral capsid proteins. A combined in s...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.09.030

    authors： Kirk K,Poh CL,Fecondo J,Pourianfar H,Shaw J,Grollo L

    更新日期：2012-11-19 00:00:00

  • Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups.

    abstract：:Following a landmark clinical trial, the vaccine against Haemophilus influenzae type b (Hib) was introduced in The Gambia in 1997. Whilst the immunogenicity of this vaccine is well established subsequent to the doses administered under the EPI schedule, little data exists assessing longevity of protection, using serol...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.06.078

    authors： Idoko OT,Roberts E,Cox M,Jafali J,Njie-Jobe J,Mackenzie G,Ota MO,Kampmann B

    更新日期：2014-08-06 00:00:00

  • Strengthening of causality assessment of adverse events following immunization in the WHO South East Asia and Western Pacific regions: Lessons from the 2014 SEAR inter-country workshop.

    abstract：BACKGROUND:Poorly managed AEFI undermine immunization programs. Improved surveillance in SEAR countries means more AEFIs but management varies. SEAR brought countries together to share AEFI experiences, and learn more about causality assessment. METHODS:Three day 10 country workshop (9 SEAR; 1 WPR). Participants outli...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.01.033

    authors： MacDonald NE,Guichard S,Amarasinghe A,Balakrishnan MR,2014 Inter-country SEAR Workshop Participants.

    更新日期：2015-11-27 00:00:00

  • A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.

    abstract：:A phase I clinical trial was performed to examine the safety and immunogenicity of a multi-epitope polypeptide comprising the central 15 amino acids of the V3 loop from six HIV-1 isolates. This protein called TAB9 was emulsified in Montanide ISA720 (Seppic, Paris) and administered intramuscularly at doses of 0, 0.2 an...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0264-410x(01)00111-6

    authors： Toledo H,Baly A,Castro O,Resik S,Laferté J,Rolo F,Navea L,Lobaina L,Cruz O,Míguez J,Serrano T,Sierra B,Pérez L,Ricardo ME,Dubed M,Lubián AL,Blanco M,Millán JC,Ortega A,Iglesias E,Pentón E,Martín Z,Pérez J,Dí

    更新日期：2001-07-20 00:00:00

  • Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody.

    abstract：:Immunogenicity of inactivated virus or subviral vaccines may be enhanced by complexing with an IgG antibody. Such antibody would increase the uptake, processing and presentation of the vaccine's antigens by antigen presenting cells (APC), via the adhesion of the antibody-vaccine complex to Fc-receptors on macrophages ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(95)00189-8

    authors： Galili U,Repik PM,Anaraki F,Mozdzanowska K,Washko G,Gerhard W

    更新日期：1996-03-01 00:00:00

  • Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia.

    abstract：:Although vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae type b (Hib) is recommended for immunocompromised patients, such as patients with B-cell chronic lymphocytic leukaemia (B-CLL), its protective effect is questionable. We studied antibody responses to pneumococcal polysacch...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0264-410x(00)00409-6

    authors： Hartkamp A,Mulder AH,Rijkers GT,van Velzen-Blad H,Biesma DH

    更新日期：2001-02-08 00:00:00

  • Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.

    abstract：:In this study, West Nile virus (WNV) envelope (rE) protein and its domain III (rDIII) were efficiently expressed in a cost-effective system based on insect larvae as non-fermentative living biofactories. Mice immunized with the partially purified rE or rDIII elicited high antibodies titers that neutralized viral infec...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.12.081

    authors： Alonso-Padilla J,de Oya NJ,Blázquez AB,Escribano-Romero E,Escribano JM,Saiz JC

    更新日期：2011-02-17 00:00:00

  • Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity.

    abstract：:In Balb/c mice, the sterile protective immunity induced by immunization with radiation-attenuated Plasmodium yoelii sporozoites is eliminated by in vivo depletion of CD8+ T lymphocytes, suggesting that cytotoxic T lymphocytes (CTL) against malaria antigens expressed on infected hepatocytes are required for mediating t...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(92)90436-n

    authors： Sedegah M,Chiang CH,Weiss WR,Mellouk S,Cochran MD,Houghten RA,Beaudoin RL,Smith D,Hoffman SL

    更新日期：1992-01-01 00:00:00

  • Case-based surveillance enhanced with measles virus detection/genotyping is essential to maintain measles elimination in Aichi Prefecture, Japan.

    abstract：BACKGROUND:Japan was verified as having achieved measles elimination by the Measles Regional Verification Commission in the Western Pacific Region in March 2015. Verification of measles elimination implies the absence of continuous endemic transmission. After the last epidemic in 2007 with an estimated 18,000 cases, Ja...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.08.070

    authors： Minagawa H,Yasui Y,Adachi H,Ito M,Hirose E,Nakamura N,Hata M,Kobayashi S,Yamashita T

    更新日期：2015-11-09 00:00:00

  • Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model.

    abstract：:We have covalently conjugated an N-terminus Plasmodium vivax apical membrane antigen-1 (AMA-1) peptide to functionalized carbon nanotubes (f-CNT). Immunological characterization of this molecular conjugate revealed that the immunogen-AMA-1 peptide was appropriately presented after being conjugated to CNTs as well as b...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.08.014

    authors： Yandar N,Pastorin G,Prato M,Bianco A,Patarroyo ME,Lozano JM

    更新日期：2008-10-29 00:00:00

  • The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.

    abstract：BACKGROUND:New, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4:IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B, formulated in IC31 adjuvant. We assessed the safety and immunogenicity of H4:IC31 in South African adult...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.05.036

    authors： Geldenhuys H,Mearns H,Miles DJ,Tameris M,Hokey D,Shi Z,Bennett S,Andersen P,Kromann I,Hoff ST,Hanekom WA,Mahomed H,Hatherill M,Scriba TJ,H4:IC31 Trial Study Group.,van Rooyen M,Bruce McClain J,Ryall R,de Bruyn G,H4:

    更新日期：2015-07-09 00:00:00

  • Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain.

    abstract：:Immunization of hairless mice with a TK-, ACVr, non-pathogenic herpes simplex virus (HSV) type 1 mutant protected the mice against reinfection with lethal doses of the parental pathogenic HSV strain. The protection conferred by the mutant against the establishment of latency after reinfection with the parental strain ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(84)90089-6

    authors： Klein RJ,Kaley LA,Friedman-Kien AE

    更新日期：1984-09-01 00:00:00

  • Protection of vaccinated mice against pneumonic tularemia is associated with an early memory sentinel-response in the lung.

    abstract：:Francisella tularensis is the intracellular bacterial pathogen causing the respiratory life-threatening disease tularemia. Development of tularemia vaccines has been hampered by an incomplete understanding of the correlates of immunity. Moreover, the importance of lung cellular immunity in vaccine-mediated protection ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.10.053

    authors： Bar-On L,Cohen H,Elia U,Rotem S,Bercovich-Kinori A,Bar-Haim E,Chitlaru T,Cohen O

    更新日期：2017-12-15 00:00:00

  • Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.

    abstract：:Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms in numerous animal and human clinical studies. The immune response induced by Ad5 vaccines can be mitigated due to pre-existing Ad5 immunity. We previously reported the use of a novel Ad5 platform to induce cellular immune responses (C...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.06.028

    authors： Gabitzsch ES,Xu Y,Yoshida LH,Balint J,Amalfitano A,Jones FR

    更新日期：2009-10-30 00:00:00

  • A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(αK): A phase I study.

    abstract：BACKGROUND:A nasal influenza vaccine has been available only in a live attenuated form, which limits the range of recipients to immune-competent individuals. The present study evaluated a newly developed intranasal inactivated influenza vaccine with a novel adjuvant, heat-labile enterotoxin (LT) derived from E. coli (L...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2019.02.006

    authors： Pan SC,Hsieh SM,Lin CF,Hsu YS,Chang M,Chang SC

    更新日期：2019-03-28 00:00:00